Nov 28, 2023 / 07:10PM GMT
Vijay Muniyappa Kumar - Evercore ISI Institutional Equities, Research Division - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team
Joining us this afternoon. I'm Vijay Kumar, the med tech and life sciences analyst at Evercore. A pleasure to have with us Hologic. From the company, we have CFO Karleen Oberton. And I think from Investor Relations, we have Ryan Simon floating around, I think, in the hallway.
Questions and Answers:
Vijay Muniyappa Kumar - Evercore ISI Institutional Equities, Research Division - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics TeamBut maybe Karleen, starting with you, I mean, fiscal '23 was really, really strong for Hologic. And in the guide -- I think when I look at your fiscal '24, excluding days, I think 5% to 8% is above your LRP rate. Comps were tougher despite that the guidance is pretty solid. And I think people are still trying to struggle with like the drivers, what has caused this turnaround rate? Let's start with molecular
Trustpilot
